Daptomycin Activity against Staphylococcus aureus following Vancomycin Exposure in an In Vitro Pharmacodynamic Model with Simulated Endocardial Vegetations
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Recently, the emergence of reduced susceptibility to daptomycin has been linked to the reduced vancomycin susceptibility that occurs after vancomycin exposure in Staphylococcus aureus in vivo and in vitro. This study evaluated this propensity in clinical isolates of S. aureus using an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations over 8 days. Five clinical isolates (four methicillin-resistant S. aureus isolates and one methicillin-susceptible S. aureus [MSSA] isolate), all of which were reported to have become nonsusceptible to daptomycin, were evaluated. The following regimens were evaluated: vancomycin 1 g every 12 h for 4 days followed by daptomycin 6 mg/kg of body weight daily for 4 days and daptomycin 6 mg/kg daily for 8 days. If nonsusceptibility was detected, the following regimens were evaluated: no treatment for 4 days followed by daptomycin 6 mg/kg daily for 4 days, vancomycin 1 g every 12 h for 4 days followed by daptomycin 10 mg/kg daily for 4 days, and daptomycin 10 mg/kg daily for 8 days. The emergence of daptomycin nonsusceptibility (12- to 16-fold MIC increase) was detected only with the MSSA isolate with daptomycin 6 mg/kg daily for 4 days after vancomycin exposure. However, the bactericidal activity of daptomycin was maintained and the MIC increases of these isolates, which had no mprF or yycG mutations, were unstable to serial passage on antibiotic-free agar. Subsequent regimens did not demonstrate nonsusceptibility to daptomycin. These findings suggest that reduced daptomycin susceptibility can be a strain-specific and unstable event. Further evaluation of the susceptibility relationship between daptomycin and vancomycin is necessary to understand the factors involved and their clinical significance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DNA sequencing with chain-terminating inhibitors
Sanger, F., Nicklen, S., & Coulson, A. R. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.12.5463 · Cited by 68,572 · cited 1×
“Nucleotide sequence analyses were performed with the DS Gene program (version 1.5; Accelrys, Inc., San Diego, CA) ( 26 ).”
MethodInfluentialA modified microtiter-plate test for quantification of staphylococcal biofilm formation
Stepanović, S., Vuković, D., Dakić, I., Savić, B., & Švabić-Vlahović, M. (2000) · Journal of Microbiological Methods · doi:10.1016/s0167-7012(00)00122-6 · Cited by 2,550
Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by Staphylococcus aureus
Fowler, V. G., Boucher, H. W., Corey, G. R., Abrutyn, E., Karchmer, A. W., Rupp, M. E., Levine, D. P., Chambers, H. F., Tally, F. P., Vigliani, G. A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053783 · Cited by 1,459
Self-citationArbeit, R. D., Maki, D., Tally, F. P., Campanaro, E., Eisenstein, B. I., & Daptomycin 98-01 and 99-01 Investigators (2004) · Clinical Infectious Diseases · doi:10.1086/420818 · Cited by 689
Correlation of Daptomycin Bactericidal Activity and Membrane Depolarization in Staphylococcus aureus
Silverman, J. A., Perlmutter, N. G., & Shapiro, H. M. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.8.2538-2544.2003 · Cited by 656
Mwangi, M. M., Wu, S. W., Zhou, Y., Sieradzki, K., de Lencastre, H., Richardson, P., Bruce, D., Rubin, E., Myers, E., Siggia, E. D., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609839104 · Cited by 538
Cell Wall Thickening Is a Common Feature of Vancomycin Resistance in Staphylococcus aureus
Cui, L., Ma, X., Sato, K., Okuma, K., Tenover, F. C., Mamizuka, E. M., Gemmell, C. G., Kim, M.-N., Ploy, M.-C., El Solh, N., et al. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.1.5-14.2003 · Cited by 492
Howden, B. P., Ward, P. B., Charles, P. G. P., Korman, T. M., Fuller, A., Cros, P. D., Grabsch, E. A., Roberts, S. A., Robson, J., Read, K., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/381202 · Cited by 484
Genetic Changes That Correlate with Reduced Susceptibility to Daptomycin in Staphylococcus aureus
Friedman, L., Alder, J. D., & Silverman, J. A. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00039-06 · Cited by 454
Cui, L., Tominaga, E., Neoh, H.-M., & Hiramatsu, K. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.3.1079-1082.2006 · Cited by 427
Charles, P. G. P., Ward, P. B., Johnson, P. D. R., Howden, B. P., & Grayson, M. L. (2004) · Clinical Infectious Diseases · doi:10.1086/381093 · Cited by 384
In Vivo Pharmacodynamic Activity of Daptomycin
Safdar, N., Andes, D., & Craig, W. A. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.1.63-68.2004 · Cited by 370
Cui, L., Murakami, H., Kuwahara-Arai, K., Hanaki, H., & Hiramatsu, K. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.9.2276-2285.2000 · Cited by 318
Sakoulas, G., Alder, J., Thauvin-Eliopoulos, C., Moellering, R. C., & Eliopoulos, G. M. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1581-1585.2006 · Cited by 262
Self-citationDaptomycin‐Resistant, Methicillin‐Resistant Staphylococcus aureus Bacteremia
Mangili, A., Bica, I., Snydman, D. R., & Hamer, D. H. (2005) · Clinical Infectious Diseases · doi:10.1086/428616 · Cited by 256
Development of Daptomycin Resistance In Vivo in Methicillin-Resistant Staphylococcus aureus
Hayden, M. K., Rezai, K., Hayes, R. A., Lolans, K., Quinn, J. P., & Weinstein, R. A. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.10.5285-5287.2005 · Cited by 241
Marty, F. M., Yeh, W. W., Wennersten, C. B., Venkataraman, L., Albano, E., Alyea, E. P., Gold, H. S., Baden, L. R., & Pillai, S. K. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.44.2.595-597.2006 · Cited by 199
Patel, J. B., Jevitt, L. A., Hageman, J., McDonald, L. C., & Tenover, F. C. (2006) · Clinical Infectious Diseases · doi:10.1086/504084 · Cited by 183
Akins, R. L., & Rybak, M. J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.2.454-459.2001 · Cited by 179
Self-citationSakoulas, G., Gold, H. S., Cohen, R. A., Venkataraman, L., Moellering, R. C., & Eliopoulos, G. M. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl030 · Cited by 149
Self-citationTsuji, B. T., & Rybak, M. J. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.7.2735-2745.2005 · Cited by 113
Self-citationDaptomycin Dose-Effect Relationship against Resistant Gram-Positive Organisms
Cha, R., Grucz, R. G., & Rybak, M. J. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.5.1598-1603.2003 · Cited by 94
Self-citationMechanisms of daptomycin resistance in Staphylococcus aureus
Kaatz, G. W., Lundstrom, T. S., & Seo, S. M. (2006) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2006.05.030 · Cited by 85
Self-citationPillai, S. K., Gold, H. S., Sakoulas, G., Wennersten, C., Moellering, R. C., & Eliopoulos, G. M. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00202-07 · Cited by 82
Self-citationRose, W. E., Rybak, M. J., & Kaatz, G. W. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm170 · Cited by 78
Self-citationWootton, M., MacGowan, A. P., & Walsh, T. R. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00678-06 · Cited by 67
Hirschwerk, D., Ginocchio, C. C., Bythrow, M., & Condon, S. (2006) · Infection Control & Hospital Epidemiology · doi:10.1086/502688 · Cited by 49
LaPlante, K. L., & Rybak, M. J. (2004) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2004.06.014 · Cited by 43
Self-citation
Research works printed but not linked: 2
- Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother. 2006
- Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother. 2006
Cited by
Habib, G., Lancellotti, P., Antunes, M. J., Bongiorni, M. G., Casalta, J.-P., Del Zotti, F., Dulgheru, R., El Khoury, G., Erba, P. A., Iung, B., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv319 · Cited by 4,997
“For this reason, daptomycin should be given at high doses (≥10 mg/kg), and most experts recommend it be combined with beta-lactams(133) or fosfomycin(134) [beta-lactams (and probably fosfomycin) increase membrane daptomycin binding by decreasing the positive surface charge] for NVE and with gentamicin and rifampin for…”
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq146 · Cited by 4,191
Self-citationBaddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Tleyjeh, I. M., Rybak, M. J., Barsic, B., Lockhart, P. B., Gewitz, M. H., Levison, M. E., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000296 · Cited by 3,232
“Histopathological evidence of bacteria with valve tissue Gram staining in patients with negative tissue cultures can represent killed organisms and is not a factor in defining the length of therapy after valve surgery.(110) For patients with NVE who undergo valve resection with prosthetic valve replacement or repair w…”
BackgroundSelf-citationGuidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009)
Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and by the International Society of Chemotherapy (ISC) for Infection and Cancer, Habib, G., Hoen, B., Tornos, P., Thuny, F., Prendergast, B., Vilacosta, I., Moreillon, P., de Jesus Antunes, M., Thilen, U., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp285 · Cited by 2,014
2023 ESC Guidelines for the management of endocarditis
Delgado, V., Ajmone Marsan, N., de Waha, S., Bonaros, N., Brida, M., Burri, H., Caselli, S., Doenst, T., Ederhy, S., Erba, P. A., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad193 · Cited by 1,754
Metadata
- Authors
- Rose, W. E., Leonard, S. N., Sakoulas, G., Kaatz, G. W., Zervos, M. J., Sheth, A., Carpenter, C. F., & Rybak, M. J.
- Affiliations
- Eugene Applebaum College of Pharmacy and Health Sciences (US)
- New York Medical College (US)
- Wayne State University (US)
- Beaumont Health (US)
- Corresponding author
- Rybak, Michael J.
- ORCID
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2008-03
- Volume
- 52
- Issue
- 3
- Pages
- 831-836
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC2258488
- OpenAlex
- W2147152367
- Semantic Scholar
- 1d34226df52261b6c8a02321749f5b66076f3f8f
- Cited by
- 81
- References
- 28
- Citations by year
- 2025: 1 · 2024: 2 · 2023: 3 · 2021: 2 · 2020: 1 · 2019: 3 · 2018: 3 · 2017: 4 · 2016: 3 · 2015: 5 · 2014: 4 · 2013: 14 · 2012: 6
- FWCI
- 4.61
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Infective Endocarditis Diagnosis and Management
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Keywords
- daptomycin, Staphylococcus aureus, endocarditis, endocardial vegetation, pharmacokinetic-pharmacodynamic modeling, methicillin-resistant Staphylococcus aureus, methicillin-susceptible Staphylococcus aureus, mprF, antibiotic resistance emergence, bactericidal activity
- MeSH terms
- Anti-Bacterial Agents, Culture Media, Drug Therapy, Combination, Endocarditis, Bacterial, Humans, Methicillin, Microbial Sensitivity Tests, Models, Biological, Staphylococcus aureus, Vancomycin, Methicillin Resistance, Daptomycin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.